case 1: nccn guidelines for treating myelofibrosis
Published 4 years ago • 233 plays • Length 2:58Download video MP4
Download video MP3
Similar videos
-
3:29
case 1: risk stratification models for myelofibrosis
-
2:08
case 1: a 68-year-old woman with primary myelofibrosis
-
5:34
treating with a jak inhibitor for myelofibrosis
-
10:42
treatment of primary myelofibrosis
-
3:42
treatment considerations in myelofibrosis
-
1:00:56
taking the targeted option for myelofibrosis
-
1:19
dr. srdan verstovsek on jak2 inhibitors as a treatment for myelofibrosis
-
4:07
diagnosis/risk classification for primary myelofibrosis
-
1:44
evolving nccn guidelines for mpns
-
1:34:09
jak inhibitors in myelofibrosis: expert insights on cases in personalizing therapy
-
3:20
thrombosis, myelofibrosis, and acute myeloid leukemia
-
1:03:11
management of myelofibrosis: jak inhibitors and novel therapeutics in the peri-transplant setting
-
4:34
considerations for jak inhibition for the treatment of pv
-
5:54
treating intermediate/high-risk primary myelofibrosis
-
55:50
drs. mesa, jamieson, & mascarenhas discuss #myelofibrosis during #asco23 - https://bit.ly/45niv2g
-
1:43
dr. tal zaks on the jak2 inhibitor sar302503 in myelofibrosis
-
37:14
risk-adapted treatment in myelofibrosis: jak inhibitors and novel combination therapies
-
6:53
case 3: prediction of thrombosis in essential thrombocythemia
-
19:37
2021 west oncology app | treatment options for elderly aml/mds patients